An observational study in Osteoporosis, Hypercalcemia and Primary Hyperparathyroidism, sponsored by Martin Blomberg Jensen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Martin Blomberg Jensen · Observational
Hormones are chemical messengers that help regulate many functions in the body. As women go through menopause, and as men age, levels of certain reproductive hormones change significantly. One of these hormones, luteinizing hormone (LH), increases substantially after menopause and may also rise in some men. Another hormone, human chorionic gonadotropin (hCG), is best known as the hormone of pregnancy, but small amounts can also be detected in some postmenopausal women and older men.
Recent research suggests that LH and hCG may have effects beyond reproduction. These hormones may influence bone health, body weight, kidney function, thyroid function, and adrenal gland function. However, little is known about their importance in patients with endocrine disorders.
The purpose of this study is to investigate whether blood levels of LH and hCG are associated with the presence, severity, and long-term outcomes of endocrine diseases. The study will include adult patients undergoing evaluation for hormonal disorders. Blood samples will be analyzed for LH, hCG, and other relevant hormones and biomarkers. Participants will also be followed through national health registries to examine whether these hormone levels are associated with future health outcomes.
The results of this study may improve our understanding of how LH and hCG affect the body and help determine whether these hormones can be used as biomarkers to improve the diagnosis and management of endocrine diseases.
The hormonal changes that occur during the menopausal transition and after menopause affect multiple organ systems and are associated with a range of symptoms and chronic diseases. The prevalence of several endocrine disorders, including hypothyroidism, primary hyperparathyroidism, osteoporosis, and adrenal tumors, increases markedly during and after menopause. In addition, postmenopausal women are at increased risk of obesity, type 2 diabetes, hypertension, cardiovascular disease, and osteoporosis. While menopausal hormone therapy can alleviate symptoms and reduce bone loss, concerns regarding breast cancer and thromboembolic risk limit its use, highlighting the need for a better understanding of the biological mechanisms underlying menopausal symptoms and long-term health complications.
Menopause is characterized not only by declining estrogen concentrations but also by a marked increase in circulating luteinizing hormone (LH). Most metabolic and skeletal changes associated with menopause have traditionally been attributed to estrogen deficiency. However, several important changes, including accelerated bone loss and weight gain, often begin during perimenopause when estrogen concentrations remain relatively stable but LH levels increase substantially. This observation suggests that elevated LH may have physiological effects beyond its established role in the reproductive system.
LH exerts its biological effects through the luteinizing hormone/choriogonadotropin receptor (LHCGR), which is also activated by human chorionic gonadotropin (hCG). Although hCG is generally considered a pregnancy-associated hormone, measurable concentrations are frequently observed in postmenopausal women and in men with hypergonadotropic hypogonadism. Emerging evidence from our group suggests that LH and hCG have previously unrecognized effects on calcium homeostasis, adipose tissue, thyroid hormone metabolism, adrenal function, and potentially the development and progression of endocrine diseases.
Experimental and clinical studies conducted by our group indicate that LH and hCG stimulate urinary calcium excretion, leading to compensatory increases in parathyroid hormone (PTH) and increased bone resorption. These findings suggest the existence of a novel physiological interaction between the hypothalamic-pituitary-gonadal axis and mineral metabolism. Such mechanisms may contribute to osteoporosis development and other disorders of calcium homeostasis, particularly in postmenopausal women exposed to prolonged elevations in LH.
In addition to skeletal effects, our data indicate that adipose tissue expresses LHCGR and responds directly to LH stimulation. Elevated LH levels may influence adipocyte function, brown adipose tissue activity, energy expenditure, weight regulation, and thyroid hormone activation through inhibition of type II iodothyronine deiodinase (DIO2). These findings suggest that LH may contribute to metabolic alterations associated with aging and menopause.
Furthermore, LHCGR expression has been identified in the adrenal gland and in a substantial proportion of benign adrenal tumors. Preliminary clinical and experimental findings indicate that LH may influence adrenal steroidogenesis and could be involved in the pathophysiology of adrenal incidentalomas, including mild autonomous cortisol secretion (MACS). Elevated LH concentrations may therefore represent a novel biomarker for adrenal dysfunction and disease progression.
Recent epidemiological evidence also suggests that elevated LH and altered testosterone-to-LH ratios are associated with increased mortality risk. Collectively, these observations support the hypothesis that LH and hCG function as systemic endocrine regulators with biological effects extending well beyond the gonads.
To further investigate this concept, we propose a prospective observational study of adult patients referred for endocrine evaluation. The study will systematically assess circulating concentrations of LH, follicle-stimulating hormone (FSH), and hCG and examine their associations with endocrine disease severity, biochemical phenotypes, and long-term clinical outcomes through linkage with national health registries. The overarching aim is to determine whether LH and hCG can serve as clinically useful biomarkers and contributors to disease mechanisms across multiple endocrine disorders.
1,601 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
This study's planned enrollment of 20,000 is above the median of 160 across 455 observational studies indexed under Osteoporosis.
Browse Osteoporosis studies →Martin Blomberg Jensen is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients referred or followed at the Department of Endocrinology and Internal Medicine, Herlev Hospital for suspected or confirmed: Osteoporosis, Hypercalcemia/PHPT, thyroid disease, adrenal disease, pituitary disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Association between serum LH and hCG and risk of major osteoporotic fracture (MOF)
Among patients with suspected or confirmed osteoporosis
Time frame: From baseline up to 5-, 10-, and 15-year follow-up
Association between serum LH and hCG and risk of later diagnosis of osteoporosis
Among patients with suspected or confirmed hypercalcemia/primary hyperparathyroidism
Time frame: From baseline up to 5-, 10-, and 15-year follow-up
Association between serum LH and hCG and urinary calcium/phosphate ratio
Among patients with suspected or confirmed hypercalcemia/primary hyperparathyroidism
Time frame: Baseline association
Association between serum LH and hCG and serum T4/T3 ratio
Among patients with suspected or confirmed thyroid disease
Time frame: Baseline association
Association between serum LH and hCG and risk of T3 treatment initiation
Among patients with suspected or confirmed thyroid disease
Time frame: From baseline up to 5-, 10-, and 15-year follow-up
Association between serum LH and hCG and risk malignant adrenal tumor
Among patients with suspected or confirmed adrenal disease
Time frame: From baseline up to 5-, 10-, and 15-year follow-up
Association between serum LH and hCG and risk of primary hyperaldosteronism
Among patients with suspected or confirmed adrenal disease
Time frame: From baseline up to 5-, 10-, and 15-year follow-up
Association between serum LH and hCG and risk of mild autonomous cortisol secretion
Among patients with suspected or confirmed adrenal disease
Time frame: From baseline up to 5-, 10-, 15-year follow-up
Plan to share: No
Started Jan 2026 (actual). Primary completion is estimated for Dec 2045, 239 months after the start.
Of 114 non-industry observational studies under Osteoporosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 113. This study's planned 239 months is above that.
Counting every sponsor, half of 125 studies reached it within 51 months; a quarter within 24 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Martin Blomberg Jensen